

# Global Non-Hodgkin Lymphoma Treatment Market Research Report 2023

https://marketpublishers.com/r/G6090BB2BF5EEN.html

Date: December 2023

Pages: 95

Price: US\$ 2,900.00 (Single User License)

ID: G6090BB2BF5EEN

#### **Abstracts**

Non-Hodgkin's lymphomas are one of the most commonly occurring cases of lymphomas and hence is also one of the most commonly occurring cancers. If not treated effectively, it is potentially lethal and leads to a shorter life span of the individuals diagnosed.

According to QYResearch's new survey, global Non-Hodgkin Lymphoma Treatment market is projected to reach US\$ 12810 million in 2029, increasing from US\$ 7891 million in 2022, with the CAGR of 7.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Non-Hodgkin Lymphoma Treatment market research.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive



to emerging public health needs.

#### Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Non-Hodgkin Lymphoma Treatment market with multiple angles, which provides sufficient supports to readers' strategy and decision making.

#### By Company





Sa	anofi	
Segment by Type		
Im	munotherapy	
Ta	argeted Therapy	
Cł	nemotherapy	
Ot	hers	
Segment by Application		
Но	ospital Pharmacies	
Re	etail Pharmacies	
Or	nline Pharmacies	
Ot	hers	
By Region	1	
No	orth America	
	United States	
	Canada	
Ει	ırope	

Germany

France



UK

OK .	
Italy	
Russia	
Nordic Countries	
Rest of Europe	
Asia-Pacific	
China	
Japan	
South Korea	
Southeast Asia	
India	
Australia	
Rest of Asia	
Latin America	
Mexico	
Brazil	
Rest of Latin America	
Middle East & Africa	
Turkey	
Saudi Arabia	



UAE

Rest of MEA

The Non-Hodgkin Lymphoma Treatment report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)

Chapter 2: Global market size, regional market size. Market Opportunities and Challenges

Chapter 3: Companies' Competition Patterns

Chapter 4: Product Type Analysis

Chapter 5: Product Application Analysis

Chapter 6 to 10: Country Level Value Analysis

Chapter 11: Companies' Outline

Chapter 12: Market Conclusions

Chapter 13: Research Methodology and Data Source



#### **Contents**

#### 1 REPORT OVERVIEW

- 1.1 Study Scope
- 1.2 Market Analysis by Type
- 1.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type:

#### 2018 VS 2022 VS 2029

- 1.2.2 Immunotherapy
- 1.2.3 Targeted Therapy
- 1.2.4 Chemotherapy
- 1.2.5 Others
- 1.3 Market by Application
- 1.3.1 Global Non-Hodgkin Lymphoma Treatment Market Growth by Application: 2018

#### VS 2022 VS 2029

- 1.3.2 Hospital Pharmacies
- 1.3.3 Retail Pharmacies
- 1.3.4 Online Pharmacies
- 1.3.5 Others
- 1.4 Study Objectives
- 1.5 Years Considered
- 1.6 Years Considered

#### **2 GLOBAL GROWTH TRENDS**

- 2.1 Global Non-Hodgkin Lymphoma Treatment Market Perspective (2018-2029)
- 2.2 Non-Hodgkin Lymphoma Treatment Growth Trends by Region
- 2.2.1 Global Non-Hodgkin Lymphoma Treatment Market Size by Region: 2018 VS 2022 VS 2029
  - 2.2.2 Non-Hodgkin Lymphoma Treatment Historic Market Size by Region (2018-2023)
- 2.2.3 Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029)
- 2.3 Non-Hodgkin Lymphoma Treatment Market Dynamics
  - 2.3.1 Non-Hodgkin Lymphoma Treatment Industry Trends
  - 2.3.2 Non-Hodgkin Lymphoma Treatment Market Drivers
  - 2.3.3 Non-Hodgkin Lymphoma Treatment Market Challenges
  - 2.3.4 Non-Hodgkin Lymphoma Treatment Market Restraints

#### **3 COMPETITION LANDSCAPE BY KEY PLAYERS**



- 3.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue
- 3.1.1 Global Top Non-Hodgkin Lymphoma Treatment Players by Revenue (2018-2023)
- 3.1.2 Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Players (2018-2023)
- 3.2 Global Non-Hodgkin Lymphoma Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.3 Players Covered: Ranking by Non-Hodgkin Lymphoma Treatment Revenue
- 3.4 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio
- 3.4.1 Global Non-Hodgkin Lymphoma Treatment Market Concentration Ratio (CR5 and HHI)
- 3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin Lymphoma Treatment Revenue in 2022
- 3.5 Non-Hodgkin Lymphoma Treatment Key Players Head office and Area Served
- 3.6 Key Players Non-Hodgkin Lymphoma Treatment Product Solution and Service
- 3.7 Date of Enter into Non-Hodgkin Lymphoma Treatment Market
- 3.8 Mergers & Acquisitions, Expansion Plans

#### 4 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY TYPE

- 4.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Type (2018-2023)
- 4.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029)

# 5 NON-HODGKIN LYMPHOMA TREATMENT BREAKDOWN DATA BY APPLICATION

- 5.1 Global Non-Hodgkin Lymphoma Treatment Historic Market Size by Application (2018-2023)
- 5.2 Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029)

#### **6 NORTH AMERICA**

- 6.1 North America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
- 6.2 North America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029



- 6.3 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
- 6.4 North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
- 6.5 United States
- 6.6 Canada

#### **7 EUROPE**

- 7.1 Europe Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
- 7.2 Europe Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 7.3 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
- 7.4 Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
- 7.5 Germany
- 7.6 France
- 7.7 U.K.
- 7.8 Italy
- 7.9 Russia
- 7.10 Nordic Countries

#### **8 ASIA-PACIFIC**

- 8.1 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
- 8.2 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
- 8.3 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023)
- 8.4 Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029)
- 8.5 China
- 8.6 Japan
- 8.7 South Korea
- 8.8 Southeast Asia
- 8.9 India
- 8.10 Australia

#### 9 LATIN AMERICA



- 9.1 Latin America Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
- 9.2 Latin America Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 9.3 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
- 9.4 Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
- 9.5 Mexico
- 9.6 Brazil

#### 10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size (2018-2029)
- 10.2 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
- 10.3 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023)
- 10.4 Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029)
- 10.5 Turkey
- 10.6 Saudi Arabia
- 10.7 UAE

#### 11 KEY PLAYERS PROFILES

- 11.1 Takeda Pharmaceutical Company Limited
- 11.1.1 Takeda Pharmaceutical Company Limited Company Detail
- 11.1.2 Takeda Pharmaceutical Company Limited Business Overview
- 11.1.3 Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Introduction
- 11.1.4 Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
- 11.1.5 Takeda Pharmaceutical Company Limited Recent Development
- 11.2 AstraZeneca
  - 11.2.1 AstraZeneca Company Detail
  - 11.2.2 AstraZeneca Business Overview
  - 11.2.3 AstraZeneca Non-Hodgkin Lymphoma Treatment Introduction
- 11.2.4 AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)



- 11.2.5 AstraZeneca Recent Development
- 11.3 Bayer
  - 11.3.1 Bayer Company Detail
  - 11.3.2 Bayer Business Overview
  - 11.3.3 Bayer Non-Hodgkin Lymphoma Treatment Introduction
  - 11.3.4 Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
- 11.3.5 Bayer Recent Development
- 11.4 Novartis AG
  - 11.4.1 Novartis AG Company Detail
  - 11.4.2 Novartis AG Business Overview
  - 11.4.3 Novartis AG Non-Hodgkin Lymphoma Treatment Introduction
- 11.4.4 Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.4.5 Novartis AG Recent Development
- 11.5 Gilead Sciences
  - 11.5.1 Gilead Sciences Company Detail
  - 11.5.2 Gilead Sciences Business Overview
  - 11.5.3 Gilead Sciences Non-Hodgkin Lymphoma Treatment Introduction
- 11.5.4 Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.5.5 Gilead Sciences Recent Development
- 11.6 Spectrum Pharmaceuticals
  - 11.6.1 Spectrum Pharmaceuticals Company Detail
  - 11.6.2 Spectrum Pharmaceuticals Business Overview
  - 11.6.3 Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
- 11.6.4 Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.6.5 Spectrum Pharmaceuticals Recent Development
- 11.7 Teva Pharmaceutical Industries Ltd.
  - 11.7.1 Teva Pharmaceutical Industries Ltd. Company Detail
  - 11.7.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 11.7.3 Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment Introduction
- 11.7.4 Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.7.5 Teva Pharmaceutical Industries Ltd. Recent Development
- 11.8 Bristol Myers Squibb Company
  - 11.8.1 Bristol Myers Squibb Company Company Detail
  - 11.8.2 Bristol Myers Squibb Company Business Overview



- 11.8.3 Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Introduction
- 11.8.4 Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.8.5 Bristol Myers Squibb Company Recent Development
- 11.9 Janssen Pharmaceuticals
  - 11.9.1 Janssen Pharmaceuticals Company Detail
  - 11.9.2 Janssen Pharmaceuticals Business Overview
  - 11.9.3 Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Introduction
- 11.9.4 Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.9.5 Janssen Pharmaceuticals Recent Development
- 11.10 Roche
  - 11.10.1 Roche Company Detail
  - 11.10.2 Roche Business Overview
  - 11.10.3 Roche Non-Hodgkin Lymphoma Treatment Introduction
  - 11.10.4 Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.10.5 Roche Recent Development
- 11.11 CELGENE CORPORATION (Bristol Myers Squibb Company)
- 11.11.1 CELGENE CORPORATION (Bristol Myers Squibb Company) Company Detail
- 11.11.2 CELGENE CORPORATION (Bristol Myers Squibb Company) Business

#### Overview

- 11.11.3 CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin Lymphoma Treatment Introduction
- 11.11.4 CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
- 11.11.5 CELGENE CORPORATION (Bristol Myers Squibb Company) Recent Development
- 11.12 Merck & Co., Inc.
  - 11.12.1 Merck & Co., Inc. Company Detail
  - 11.12.2 Merck & Co., Inc. Business Overview
  - 11.12.3 Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Introduction
- 11.12.4 Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.12.5 Merck & Co., Inc. Recent Development
- 11.13 Kyowa Kirin Co., Ltd.
  - 11.13.1 Kyowa Kirin Co., Ltd. Company Detail
  - 11.13.2 Kyowa Kirin Co., Ltd. Business Overview
- 11.13.3 Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Introduction



- 11.13.4 Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.13.5 Kyowa Kirin Co., Ltd. Recent Development
- 11.14 AbbVie
  - 11.14.1 AbbVie Company Detail
  - 11.14.2 AbbVie Business Overview
  - 11.14.3 AbbVie Non-Hodgkin Lymphoma Treatment Introduction
  - 11.14.4 AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
  - 11.14.5 AbbVie Recent Development
- 11.15 Sanofi
- 11.15.1 Sanofi Company Detail
- 11.15.2 Sanofi Business Overview
- 11.15.3 Sanofi Non-Hodgkin Lymphoma Treatment Introduction
- 11.15.4 Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)
- 11.15.5 Sanofi Recent Development

#### 12 ANALYST'S VIEWPOINTS/CONCLUSIONS

#### 13 APPENDIX

- 13.1 Research Methodology
  - 13.1.1 Methodology/Research Approach
  - 13.1.2 Data Source
- 13.2 Disclaimer
- 13.3 Author Details



#### **List Of Tables**

#### LIST OF TABLES

Table 1. Global Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Type (US\$ Million): 2018 VS 2022 VS 2029

Table 2. Key Players of Immunotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Key Players of Chemotherapy

Table 5. Key Players of Others

Table 6. Global Non-Hodgkin Lymphoma Treatment Market Size Growth by Application (US\$ Million): 2018 VS 2022 VS 2029

Table 7. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (US\$

Million): 2018 VS 2022 VS 2029

Table 8. Global Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US\$ Million)

Table 9. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2023)

Table 10. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Region (2024-2029) & (US\$ Million)

Table 11. Global Non-Hodgkin Lymphoma Treatment Market Share by Region (2024-2029)

Table 12. Non-Hodgkin Lymphoma Treatment Market Trends

Table 13. Non-Hodgkin Lymphoma Treatment Market Drivers

Table 14. Non-Hodgkin Lymphoma Treatment Market Challenges

Table 15. Non-Hodgkin Lymphoma Treatment Market Restraints

Table 16. Global Non-Hodgkin Lymphoma Treatment Revenue by Players (2018-2023) & (US\$ Million)

Table 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players (2018-2023)

Table 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)

Table 19. Ranking of Global Top Non-Hodgkin Lymphoma Treatment Companies by Revenue (US\$ Million) in 2022

Table 20. Global 5 Largest Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue (CR5 and HHI) & (2018-2023)

Table 21. Key Players Headquarters and Area Served

Table 22. Key Players Non-Hodgkin Lymphoma Treatment Product Solution and



#### Service

- Table 23. Date of Enter into Non-Hodgkin Lymphoma Treatment Market
- Table 24. Mergers & Acquisitions, Expansion Plans
- Table 25. Global Non-Hodgkin Lymphoma Treatment Market Size by Type (2018-2023) & (US\$ Million)
- Table 26. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2018-2023)
- Table 27. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Type (2024-2029) & (US\$ Million)
- Table 28. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Type (2024-2029)
- Table 29. Global Non-Hodgkin Lymphoma Treatment Market Size by Application (2018-2023) & (US\$ Million)
- Table 30. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2018-2023)
- Table 31. Global Non-Hodgkin Lymphoma Treatment Forecasted Market Size by Application (2024-2029) & (US\$ Million)
- Table 32. Global Non-Hodgkin Lymphoma Treatment Revenue Market Share by Application (2024-2029)
- Table 33. North America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 34. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US\$ Million)
- Table 35. North America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US\$ Million)
- Table 36. Europe Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029
- Table 37. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US\$ Million)
- Table 38. Europe Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US\$ Million)
- Table 39. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Region (US\$ Million): 2018 VS 2022 VS 2029
- Table 40. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2018-2023) & (US\$ Million)
- Table 41. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size by Region (2024-2029) & (US\$ Million)
- Table 42. Latin America Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029



Table 43. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 44. Latin America Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size Growth Rate by Country (US\$ Million): 2018 VS 2022 VS 2029

Table 46. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2018-2023) & (US\$ Million)

Table 47. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size by Country (2024-2029) & (US\$ Million)

Table 48. Takeda Pharmaceutical Company Limited Company Detail

Table 49. Takeda Pharmaceutical Company Limited Business Overview

Table 50. Takeda Pharmaceutical Company Limited Non-Hodgkin Lymphoma Treatment Product

Table 51. Takeda Pharmaceutical Company Limited Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US\$ Million)

Table 52. Takeda Pharmaceutical Company Limited Recent Development

Table 53. AstraZeneca Company Detail

Table 54. AstraZeneca Business Overview

Table 55. AstraZeneca Non-Hodgkin Lymphoma Treatment Product

Table 56. AstraZeneca Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US\$ Million)

Table 57. AstraZeneca Recent Development

Table 58. Bayer Company Detail

Table 59. Bayer Business Overview

Table 60. Bayer Non-Hodgkin Lymphoma Treatment Product

Table 61. Bayer Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US\$ Million)

Table 62. Bayer Recent Development

Table 63. Novartis AG Company Detail

Table 64. Novartis AG Business Overview

Table 65. Novartis AG Non-Hodgkin Lymphoma Treatment Product

Table 66. Novartis AG Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US\$ Million)

Table 67. Novartis AG Recent Development

Table 68. Gilead Sciences Company Detail

Table 69. Gilead Sciences Business Overview

Table 70. Gilead Sciences Non-Hodgkin Lymphoma Treatment Product

Table 71. Gilead Sciences Revenue in Non-Hodgkin Lymphoma Treatment Business



(2018-2023) & (US\$ Million)

Table 72. Gilead Sciences Recent Development

Table 73. Spectrum Pharmaceuticals Company Detail

Table 74. Spectrum Pharmaceuticals Business Overview

Table 75. Spectrum Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product

Table 76. Spectrum Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment

Business (2018-2023) & (US\$ Million)

Table 77. Spectrum Pharmaceuticals Recent Development

Table 78. Teva Pharmaceutical Industries Ltd. Company Detail

Table 79. Teva Pharmaceutical Industries Ltd. Business Overview

Table 80. Teva Pharmaceutical Industries Ltd. Non-Hodgkin Lymphoma Treatment

Product

Table 81. Teva Pharmaceutical Industries Ltd. Revenue in Non-Hodgkin Lymphoma

Treatment Business (2018-2023) & (US\$ Million)

Table 82. Teva Pharmaceutical Industries Ltd. Recent Development

Table 83. Bristol Myers Squibb Company Company Detail

Table 84. Bristol Myers Squibb Company Business Overview

Table 85. Bristol Myers Squibb Company Non-Hodgkin Lymphoma Treatment Product

Table 86. Bristol Myers Squibb Company Revenue in Non-Hodgkin Lymphoma

Treatment Business (2018-2023) & (US\$ Million)

Table 87. Bristol Myers Squibb Company Recent Development

Table 88. Janssen Pharmaceuticals Company Detail

Table 89. Janssen Pharmaceuticals Business Overview

Table 90. Janssen Pharmaceuticals Non-Hodgkin Lymphoma Treatment Product

Table 91. Janssen Pharmaceuticals Revenue in Non-Hodgkin Lymphoma Treatment

Business (2018-2023) & (US\$ Million)

Table 92. Janssen Pharmaceuticals Recent Development

Table 93. Roche Company Detail

Table 94. Roche Business Overview

Table 95. Roche Non-Hodgkin Lymphoma Treatment Product

Table 96. Roche Revenue in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

& (US\$ Million)

Table 97. Roche Recent Development

Table 98. CELGENE CORPORATION (Bristol Myers Squibb Company) Company

Detail

Table 99. CELGENE CORPORATION (Bristol Myers Squibb Company) Business

Overview

Table 100. CELGENE CORPORATION (Bristol Myers Squibb Company) Non-Hodgkin

Lymphoma Treatment Product



Table 101. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue in

Non-Hodgkin Lymphoma Treatment Business (2018-2023) & (US\$ Million)

Table 102. CELGENE CORPORATION (Bristol Myers Squibb Company) Recent

Development

Table 103. Merck & Co., Inc. Company Detail

Table 104. Merck & Co., Inc. Business Overview

Table 105. Merck & Co., Inc. Non-Hodgkin Lymphoma Treatment Product

Table 106. Merck & Co., Inc. Revenue in Non-Hodgkin Lymphoma Treatment Business

(2018-2023) & (US\$ Million)

Table 107. Merck & Co., Inc. Recent Development

Table 108. Kyowa Kirin Co., Ltd. Company Detail

Table 109. Kyowa Kirin Co., Ltd. Business Overview

Table 110. Kyowa Kirin Co., Ltd. Non-Hodgkin Lymphoma Treatment Product

Table 111. Kyowa Kirin Co., Ltd. Revenue in Non-Hodgkin Lymphoma Treatment

Business (2018-2023) & (US\$ Million)

Table 112. Kyowa Kirin Co., Ltd. Recent Development

Table 113. AbbVie Company Detail

Table 114. AbbVie Business Overview

Table 115. AbbVie Non-Hodgkin Lymphoma Treatment Product

Table 116. AbbVie Revenue in Non-Hodgkin Lymphoma Treatment Business

(2018-2023) & (US\$ Million)

Table 117. AbbVie Recent Development

Table 118. Sanofi Company Detail

Table 119. Sanofi Business Overview

Table 120. Sanofi Non-Hodgkin Lymphoma Treatment Product

Table 121. Sanofi Revenue in Non-Hodgkin Lymphoma Treatment Business

(2018-2023) & (US\$ Million)

Table 122. Sanofi Recent Development

Table 123. Research Programs/Design for This Report

Table 124. Key Data Information from Secondary Sources

Table 125. Key Data Information from Primary Sources



## **List Of Figures**

#### **LIST OF FIGURES**

Figure 1. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Type (2023-2029) & (US\$ Million)

Figure 2. Global Non-Hodgkin Lymphoma Treatment Market Share by Type: 2022 VS 2029

Figure 3. Immunotherapy Features

Figure 4. Targeted Therapy Features

Figure 5. Chemotherapy Features

Figure 6. Others Features

Figure 7. Global Non-Hodgkin Lymphoma Treatment Market Size Comparison by Application (2023-2029) & (US\$ Million)

Figure 8. Global Non-Hodgkin Lymphoma Treatment Market Share by Application: 2022 VS 2029

Figure 9. Hospital Pharmacies Case Studies

Figure 10. Retail Pharmacies Case Studies

Figure 11. Online Pharmacies Case Studies

Figure 12. Others Case Studies

Figure 13. Non-Hodgkin Lymphoma Treatment Report Years Considered

Figure 14. Global Non-Hodgkin Lymphoma Treatment Market Size (US\$ Million), Year-over-Year: 2018-2029

Figure 15. Global Non-Hodgkin Lymphoma Treatment Market Size, (US\$ Million), 2018 VS 2022 VS 2029

Figure 16. Global Non-Hodgkin Lymphoma Treatment Market Share by Region: 2022 VS 2029

Figure 17. Global Non-Hodgkin Lymphoma Treatment Market Share by Players in 2022

Figure 18. Global Top Non-Hodgkin Lymphoma Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin Lymphoma Treatment as of 2022)

Figure 19. The Top 10 and 5 Players Market Share by Non-Hodgkin Lymphoma Treatment Revenue in 2022

Figure 20. North America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 21. North America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)

Figure 22. United States Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)



Figure 23. Canada Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 24. Europe Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 25. Europe Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)

Figure 26. Germany Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 27. France Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 28. U.K. Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 29. Italy Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 30. Russia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 31. Nordic Countries Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 32. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 33. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market Share by Region (2018-2029)

Figure 34. China Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 35. Japan Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 36. South Korea Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 37. Southeast Asia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 38. India Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 39. Australia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 40. Latin America Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 41. Latin America Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)

Figure 42. Mexico Non-Hodgkin Lymphoma Treatment Market Size YoY Growth



(2018-2029) & (US\$ Million)

Figure 43. Brazil Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 44. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 45. Middle East & Africa Non-Hodgkin Lymphoma Treatment Market Share by Country (2018-2029)

Figure 46. Turkey Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 47. Saudi Arabia Non-Hodgkin Lymphoma Treatment Market Size YoY Growth (2018-2029) & (US\$ Million)

Figure 48. Takeda Pharmaceutical Company Limited Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 49. AstraZeneca Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 50. Bayer Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 51. Novartis AG Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 52. Gilead Sciences Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 53. Spectrum Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 54. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 55. Bristol Myers Squibb Company Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 56. Janssen Pharmaceuticals Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 57. Roche Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 58. CELGENE CORPORATION (Bristol Myers Squibb Company) Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 59. Merck & Co., Inc. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 60. Kyowa Kirin Co., Ltd. Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 61. AbbVie Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)



Figure 62. Sanofi Revenue Growth Rate in Non-Hodgkin Lymphoma Treatment Business (2018-2023)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed



#### I would like to order

Product name: Global Non-Hodgkin Lymphoma Treatment Market Research Report 2023

Product link: https://marketpublishers.com/r/G6090BB2BF5EEN.html

Price: US\$ 2,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

### **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/G6090BB2BF5EEN.html">https://marketpublishers.com/r/G6090BB2BF5EEN.html</a>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <a href="https://marketpublishers.com/docs/terms.html">https://marketpublishers.com/docs/terms.html</a>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970